Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant

Takahiko Nakane, Takahiro Fukuda, Junya Kanda, Shuichi Taniguchi, Tetsuya Eto, Kazuteru Ohashi, Hirohisa Nakamae, Mineo Kurokawa, Takehiko Mori, Yasuo Morishima, Tokiko Nagamura-Inoue, Hisashi Sakamaki, Yoshiko Atsuta, Makoto Murata

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We retrospectively analyzed 2682 patients who developed grade II-IV acute graft-versus-host disease (GVHD). On analysis with stratification into five age groups (20-29, 30-39, 40-49, 50-59 and ≥ 60), 2-year non-relapse mortality rates (NRM) after the onset of GVHD were 20.7, 26.2, 26.6, 37.0 and 40.4%, respectively (p <0.001). We found a significant interaction between the patient's age and GVHD severity with respect to NRM (p = 0.004). On multivariate analyses stratified by GVHD severity, the hazard ratio (HR) for NRM in the groups aged 50 years or more (reference: age group 20-29) was about twice as great in patients with grade II acute GVHD when compared with grade III-IV disease (HR in those aged 50-59 years: 2.9 for grade II and 1.5 [p = 0.03 and 0.04] for grades III-IV; HR if ≥ 60 years: 3.3 for grade II and 1.5 for grades III-IV [p <0.001 for both]).

Original languageEnglish
Pages (from-to)2392-2397
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number8
DOIs
Publication statusPublished - 2015 Aug 3

    Fingerprint

Keywords

  • Clinical results
  • graft-versus-host disease
  • transplant toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Nakane, T., Fukuda, T., Kanda, J., Taniguchi, S., Eto, T., Ohashi, K., Nakamae, H., Kurokawa, M., Mori, T., Morishima, Y., Nagamura-Inoue, T., Sakamaki, H., Atsuta, Y., & Murata, M. (2015). Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 56(8), 2392-2397. https://doi.org/10.3109/10428194.2015.1009056